% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mariz:182177,
      author       = {F. C. Mariz$^*$ and K. Balz$^*$ and M. Dittrich$^*$ and Y.
                      Zhang$^*$ and F. Yang$^*$ and X. Zhao$^*$ and A. Bolchi and
                      S. Ottonello and M. Müller$^*$},
      title        = {{A} broadly protective vaccine against cutaneous human
                      papillomaviruses.},
      journal      = {npj vaccines},
      volume       = {7},
      number       = {1},
      issn         = {2059-0105},
      address      = {[London]},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2022-02479},
      pages        = {116},
      year         = {2022},
      note         = {#EA:F035#LA:F035#},
      abstract     = {Skin colonization by human papillomavirus (HPV) is
                      typically related to inconspicuous cutaneous infections
                      without major disease or complications in immunocompetent
                      individuals. However, in immunosuppressed patients,
                      especially organ transplanted recipients, cutaneous HPV
                      infections may cause massive, highly spreading and recurrent
                      skin lesions upon synergism with UV-exposure. Current HPV
                      prophylactic vaccines are not effective against cutaneous
                      HPV types (cHPV). By applying a modular polytope-based
                      approach, in this work, we explored different vaccine
                      candidates based on selected, tandemly arranged cHPV-L2
                      epitopes fused to thioredoxin (Trx) as a scaffold protein.
                      Upon conversion to heptameric nanoparticles with the use of
                      a genetically fused oligomerization domain, our candidate
                      Trx-L2 vaccines induce broadly neutralizing immune responses
                      against 19 cHPV in guinea pigs. Similar findings were
                      obtained in mice, where protection against virus challenge
                      was also achieved via passive transfer of immune sera.
                      Remarkably, immunization with the candidate cHPV vaccines
                      also induced immune responses against several mucosal low-
                      and high-risk HPV types, including HPV16 and 18. Based on
                      cumulative immunogenicity data but also on ease and yield of
                      production, we identified a lead vaccine candidate bearing
                      12 different cHPV-L2 epitopes that holds great promise as a
                      scalable and GMP production-compatible lead molecule for the
                      prevention of post-transplantation skin lesions caused by
                      cHPV infection.},
      cin          = {F035},
      ddc          = {610},
      cid          = {I:(DE-He78)F035-20160331},
      pnm          = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
      pid          = {G:(DE-HGF)POF4-316},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36216845},
      pmc          = {pmc:PMC9550855},
      doi          = {10.1038/s41541-022-00539-0},
      url          = {https://inrepo02.dkfz.de/record/182177},
}